TCRT (Alaunos Therapeutics) Market Cap: $5.25 Mil (As of Jun. 25, 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.15
GF Value $0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Market Cap?

Alaunos Therapeutics TCRT -0.18% 28 Market Cap is $5.25 Mil as of Jun. 25, 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,430 Biotechnology companies, Alaunos Therapeutics ranks worse than 90.63% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alaunos Therapeutics's share price for the quarter that ended in Mar. 2026 was $2.86. Alaunos Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.38 Mil. Therefore, Alaunos Therapeutics's market cap for the quarter that ended in Mar. 2026 was $6.80 Mil.

Alaunos Therapeutics's quarterly market cap increased from Sep. 2025 ($5.32 Mil) to Dec. 2025 ($7.59 Mil) but then declined from Dec. 2025 ($7.59 Mil) to Mar. 2026 ($6.80 Mil).

Alaunos Therapeutics's annual market cap declined from Dec. 2023 ($16.98 Mil) to Dec. 2024 ($3.05 Mil) but then increased from Dec. 2024 ($3.05 Mil) to Dec. 2025 ($7.59 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alaunos Therapeutics's Enterprise Value for Today is $4.90 Mil.


Alaunos Therapeutics  (NAS:TCRT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Alaunos Therapeutics Market Cap Related Terms


Alaunos Therapeutics Market Cap Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Market Cap Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.60 156.08 16.98 3.05 7.59

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 10.06 5.32 7.59 6.80

TCRT vs ASBP, SILO, PCSA: Market Cap Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Market Cap falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alaunos Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=$3.23*2.349
=$7.59

Alaunos Therapeutics's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=$2.86*2.378
=$6.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $5.25 Mil mean?
Alaunos Therapeutics (TCRT) has a Market Cap of $5.25 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alaunos Therapeutics and its competitors. According to the industry distribution chart, Alaunos Therapeutics ranks #1296 out of 1430 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Alaunos Therapeutics' Market Cap too high?
Alaunos Therapeutics' current Market Cap is $5.25 Mil. The Biotechnology industry median Market Cap is 117.26. Alaunos Therapeutics' value of $5.25 Mil is 95.5% below this industry median. Based on the distribution chart, Alaunos Therapeutics ranks #1296 out of 1430 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Market Cap compare to ASBP and SILO?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #1296 out of 1430 companies for Market Cap. This places Alaunos Therapeutics in the lower half of its industry. The industry median Market Cap is 117.26. Alaunos Therapeutics' value of $5.25 Mil is 95.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alaunos Therapeutics's current Market Cap of $5.25 Mil is 95.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alaunos Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alaunos Therapeutics's current Market Cap is $5.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $2.15 — trading 211.6% above its estimated fair value. The current Market Cap is $5.25 Mil and 95.5% below the Biotechnology industry median of 117.26. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Market Cap is $5.25 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.15 is trading 211.6% above its estimated GF Value™ of $0.69. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Market Cap: $5.25 Mil
  • GF Value™: $0.69 vs. price of $2.15 (211.6% above fair value)
  • GF Score™: 28/100 with 4 warning signs
  • Industry Position: 95.5% below the Biotechnology median (#1296 of 1430)

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15
Price
$0.69
GF Value